Olaratumab Disease Interactions
There are 2 disease interactions with olaratumab.
Olaratumab (applies to olaratumab) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Olaratumab population pharmacokinetic analysis in patients with mild to moderate hepatic impairment indicated that hepatic impairment had no clinically important effect on the pharmacokinetics of olaratumab. The pharmacokinetics of olaratumab in patients with severe hepatic impairment is unknown. Care and close monitoring should be exercised when using this agent in patients with severe hepatic impairment.
Olaratumab (applies to olaratumab) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Olaratumab population pharmacokinetic analysis in patients with mild to moderate renal impairment indicated that renal impairment had no clinically important effect on the pharmacokinetics of olaratumab. The pharmacokinetics of olaratumab in patients with severe renal impairment is unknown. Care and close monitoring should be exercised when using this agent in patients with severe renal impairment.
Switch to professional interaction data
Olaratumab drug interactions
There are 165 drug interactions with olaratumab.
Report options
More about olaratumab
- olaratumab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Votrient
Votrient is used to treat renal cell carcinoma (kidney cancer). Learn about side effects ...
Caplyta
Caplyta is used to treat schizophrenia or depression associated with bipolar disorder. It is taken ...
Yondelis
Yondelis (trabectedin) is used to treat liposarcoma or leiomyosarcoma, two common subtypes of soft ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Tecentriq Hybreza
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous formulation of Tecentriq ...
Atezolizumab/hyaluronidase
Atezolizumab/hyaluronidase is used for alveolar soft part sarcoma, hepatocellular carcinoma ...
Atezolizumab
Atezolizumab (Tecentriq) is a type of immunotherapy drug that helps the body's immune system to ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.